DOCSLIB.ORG

PI3K/AKT, MAPK and AMPK Signalling: Protein Kinases in Glucose Homeostasis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PI3K/AKT, MAPK and AMPK Signalling: Protein Kinases in Glucose Homeostasis Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2012 PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis Schultze, S M ; Hemmings, B A ; Niessen, M ; Tschopp, O Abstract: New therapeutic approaches to counter the increasing prevalence of obesity and type 2 diabetes mellitus are in high demand. Deregulation of the phosphoinositide-3-kinase (PI3K)/v-akt murine thy- moma viral oncogene homologue (AKT), mitogen-activated protein kinase (MAPK) and AMP-activated protein kinase (AMPK) pathways, which are essential for glucose homeostasis, often results in obesity and diabetes. Thus, these pathways should be attractive therapeutic targets. However, with the excep- tion of metformin, which is considered to function mainly by activating AMPK, no treatment for the metabolic syndrome based on targeting protein kinases has yet been developed. By contrast, therapies based on the inhibition of the PI3K/AKT and MAPK pathways are already successful in the treatment of diverse cancer types and inflammatory diseases. This contradiction prompted us to review the signal transduction mechanisms of PI3K/AKT, MAPK and AMPK and their roles in glucose homeostasis, and we also discuss current clinical implications. DOI: https://doi.org/10.1017/S1462399411002109 Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-56698 Journal Article Published Version Originally published at: Schultze, S M; Hemmings, B A; Niessen, M; Tschopp, O (2012). PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis. Expert Reviews in Molecular Medicine, 14:e1. DOI: https://doi.org/10.1017/S1462399411002109 expert reviews http://www.expertreviews.org/ in molecular medicine PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis Simon M. Schultze1,2, Brian A. Hemmings2, Markus Niessen1 and Oliver Tschopp1,* New therapeutic approaches to counter the increasing prevalence of obesity glucose homeostasis and type 2 diabetes mellitus are in high demand. Deregulation of the phosphoinositide-3-kinase (PI3K)/v-akt murine thymoma viral oncogene homologue (AKT), mitogen-activated protein kinase (MAPK) and AMP-activated protein kinase (AMPK) pathways, which are essential for glucose homeostasis, often results in obesity and diabetes. Thus, these pathways should be attractive therapeutic targets. However, with the exception of metformin, which is considered to function mainly by activating AMPK, no treatment for the metabolic syndrome based on targeting protein kinases has yet been developed. By contrast, therapies based on the inhibition of the PI3K/AKT and MAPK pathways are already successful in the treatment of diverse cancer types and inflammatory diseases. This contradiction prompted us to review the signal transduction mechanisms of PI3K/AKT, MAPK and AMPK and their roles in glucose homeostasis, and we also discuss current clinical implications. Metabolic syndrome is generally defined as a coronary heart disease, stroke and nonalcoholic cluster of risk factors for cardiovascular disease fatty liver disease (Refs 3, 4, 5). and type 2 diabetes mellitus (T2DM) including Strict control of the level of circulating glucose central obesity, arterial hypertension, within a narrow physiological range supplies dyslipidaemia and elevated fasting glucose sufficient energy for organs and avoids (Ref. 1). Impaired glucose homeostasis, as hyperglycaemia. Glucose homeostasis is largely observed in patients with metabolic syndrome, maintained by the insulin–glucagon system, PI3K/AKT, MAPK and AMPK signalling: protein kinases in frequently progresses to overt T2DM, which in which compensates for physiological 2010 affected 344 million patients worldwide fluctuations in blood glucose caused by food (Ref. 2). Hyperglycaemia in diabetic patients can intake and physical activity, or by stress lead to life-threatening complications such as conditions such as hypoxia and inflammation. 1Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital of Zurich, Zurich, Switzerland 2Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland *Corresponding author: Oliver Tschopp, Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital of Zurich, Raemistrasse 100, 8091 Zurich, Switzerland. E-mail: oliver.tschopp@ usz.ch 1 Accession information: doi:10.1017/S1462399411002109; Vol. 14; e1; January 2012 © Cambridge University Press 2012 expert reviews http://www.expertreviews.org/ in molecular medicine Insulin and glucagon are released from β- and α- for proper metabolic control and their cells, respectively, in the endocrine part of the dysfunction often leads to impaired glucose pancreas. Insulin lowers blood glucose by homeostasis, these pathways are attractive stimulating glucose uptake and storage therapeutic targets (Refs 8, 9, 10). However, (glycogen synthesis and lipogenesis) in skeletal PI3K/AKT, MAPK and AMPK are also involved muscle and adipose tissue. In the liver, insulin in several other fundamental cellular processes, blocks the release and neogenesis of glucose and including cell proliferation and survival, and stimulates glucose storage. In addition, insulin thus global therapeutic modification of their stimulates protein synthesis, regulates activities could induce severe side effects. mitochondrial biogenesis and blocks autophagy. Today, specific kinase inhibitors are used Glucagon antagonises the action of insulin, successfully for immunosuppression and in the mostly in the liver, where it stimulates treatment of inflammatory disease and diverse gluconeogenesis and thereby increases blood cancer types. However, because proper glucose level. The secretion of insulin and activation of the PI3K/AKT pathway is required glucagon is regulated in a reciprocal manner, for insulin action, kinase inhibitors targeting glucose homeostasis which avoids glycaemic volatility because of PI3K/AKT and downstream effectors might their opposing effects. It was proposed that the impair metabolic control. Even though glucose-induced secretion of insulin inhibits inappropriate activation of MAPKs, especially of glucagon secretion from α-cells in a paracrine c-Jun N-terminal kinase (MAPK8, JNK), is manner (Ref. 6). Furthermore, incretin hormones considered to have a critical role in acquired [e.g. glucagon-like peptide 1 (GLP-1)] secreted insulin resistance, no therapies based on MAPKs postprandially by the gut potentiate glucose- are available so far. The only drug targeting mediated insulin secretion and block glucagon protein kinase activity that is widely used today secretion (Ref. 7). In addition, physiological in the treatment of insulin resistance and conditions such as low intracellular energy level diabetes is metformin, which is thought to and cellular stress affect whole-body glucose operate mainly by activating AMPK. Although homeostasis by interfering with insulin action. our understanding of the role of protein kinases Signal transduction from a stimulus to the in the regulation of glucose homeostasis has regulation of cellular processes, including those increased significantly during the past decade, involved in glucose homeostasis, is primarily only limited translation into therapies against dependent on protein kinase signalling. On the metabolic syndrome has occurred. The activation, protein kinases determine the output purpose of this present review is to summarise of metabolic processes by transcriptional and the signal transduction mechanisms involving post-translational regulation of rate-limiting PI3K/AKT, MAPK and AMPK with respect to enzymes, such as glycogen synthase 1 their role in glucose homeostasis and to discuss (GYS1) and fatty acid synthase (FASN, FAS). current clinical implications. The insulin receptor (INSR, IR) activates various downstream pathways that control The PI3K–AKT signalling pathway is the energy homeostasis, including major effector of metabolic insulin action phosphoinositide-3-kinase (PI3K)/v-akt murine Insulin is an indispensable regulator of glucose PI3K/AKT, MAPK and AMPK signalling: protein kinases in thymoma viral oncogene homologue [AKT, also homeostasis, and T2DM is characterised by known as protein kinase B (PKB)] and the postreceptor insulin resistance combined with β- mitogen-activated protein kinase 3/1 (MAPK3/ cell failure. Insulin signalling is initiated by the 1, ERK1/2). Whereas the PI3K/AKT pathway is binding of insulin to the extracellular α-subunits considered to be the major effector of metabolic of the heterotetrameric IR. This interaction insulin action, insulin-independent kinases also induces conformational changes and facilitates contribute to metabolic control. AMP-activated autophosphorylation of tyrosine residues on protein kinase (AMPK) is mostly activated by the intracellular part of membrane-spanning low intracellular energy levels and inhibits β-subunits. These phosphotyrosines then attract anabolic processes, stimulates energy-producing a family of adaptor molecules, the insulin catabolic processes and lowers blood glucose receptor substrates (IRSs). On interaction with level. Because correct functioning of the PI3K/ the IR, IRS proteins themselves are tyrosine AKT, MAPK and AMPK pathways is essential phosphorylated, which is partially mediated by 2 Accession information: doi:10.1017/S1462399411002109; Vol. 14; e1; January 2012 © Cambridge University Press 2012 expert reviews http://www.expertreviews.org/
Load more

Recommended publications
  • Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB
    Table S1. Kinase clones included in human kinase cDNA library for yeast two-hybrid screening Gene Symbol Gene Description ACVR1B activin A receptor, type IB ADCK2 aarF domain containing kinase 2 ADCK4 aarF domain containing kinase 4 AGK multiple substrate lipid kinase;MULK AK1 adenylate kinase 1 AK3 adenylate kinase 3 like 1 AK3L1 adenylate kinase 3 ALDH18A1 aldehyde dehydrogenase 18 family, member A1;ALDH18A1 ALK anaplastic lymphoma kinase (Ki-1) ALPK1 alpha-kinase 1 ALPK2 alpha-kinase 2 AMHR2 anti-Mullerian hormone receptor, type II ARAF v-raf murine sarcoma 3611 viral oncogene homolog 1 ARSG arylsulfatase G;ARSG AURKB aurora kinase B AURKC aurora kinase C BCKDK branched chain alpha-ketoacid dehydrogenase kinase BMPR1A bone morphogenetic protein receptor, type IA BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) BRAF v-raf murine sarcoma viral oncogene homolog B1 BRD3 bromodomain containing 3 BRD4 bromodomain containing 4 BTK Bruton agammaglobulinemia tyrosine kinase BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) C9orf98 chromosome 9 open reading frame 98;C9orf98 CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe) CALM1 calmodulin 1 (phosphorylase kinase, delta) CALM2 calmodulin 2 (phosphorylase kinase, delta) CALM3 calmodulin 3 (phosphorylase kinase, delta) CAMK1 calcium/calmodulin-dependent protein kinase I CAMK2A calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha CAMK2B calcium/calmodulin-dependent
    [Show full text]
  • Brief Genetics Report Haplotype Structures and Large
    Brief Genetics Report Haplotype Structures and Large-Scale Association Testing of the 5؅ AMP-Activated Protein Kinase Genes PRKAA2, PRKAB1, and PRKAB2 With Type 2 Diabetes Maria W. Sun,1,2 Jennifer Y. Lee,1,2 Paul I.W. de Bakker,1,2,3 Noe¨l P. Burtt,2 Peter Almgren,4 Lennart Råstam,5 Tiinamaija Tuomi,6 Daniel Gaudet,7 Mark J. Daly,2,8 Joel N. Hirschhorn,2,3,9 David Altshuler,1,2,3,8,10 Leif Groop,4,6 and Jose C. Florez1,2,8,10 AMP-activated protein kinase (AMPK) is a key molecular plasma glucose, or insulin sensitivity. Several nominal asso- regulator of cellular metabolism, and its activity is induced ciations of variants in PRKAA2 and PRKAB1 with BMI appear by both metformin and thiazolidinedione antidiabetic med- to be consistent with statistical noise. Diabetes 55:849–855, ications. It has therefore been proposed both as a putative 2006 agent in the pathophysiology of type 2 diabetes and as a valid target for therapeutic intervention. Thus, the genes that encode the various AMPK subunits are intriguing ype 2 diabetes arises from the complex interplay candidates for the inherited basis of type 2 diabetes. We therefore set out to test for the association of common of various pathophysiologic mechanisms involv- variants in the genes that encode three selected AMPK ing peripheral insulin resistance and relative subunits with type 2 diabetes and related phenotypes. Of Tinsulin insufficiency. The final expression of the the seven genes that encode AMPK isoforms, we initially diabetic phenotype is strongly influenced by inheritance; chose PRKAA2, PRKAB1, and PRKAB2 because of their however, with the exception of rare monogenic forms of higher prior probability of association with type 2 diabetes, diabetes, common type 2 diabetes is thought to have a based on previous reports of genetic linkage, functional polygenic architecture (1).
    [Show full text]
  • Adrenocortical Tumors Have a Distinct Long Non-Coding RNA Expression Profile and LINC00271 Is Downregulated in Malignancy
    Edinburgh Research Explorer Adrenocortical tumors have a distinct long non-coding RNA expression profile and LINC00271 is downregulated in malignancy Citation for published version: Buishand, F, Liu-Chittenden, Y, Fan, Y, Tirosh, A, Gara, S, Patel, D, Meerzaman, D & Kebebew, E 2019, 'Adrenocortical tumors have a distinct long non-coding RNA expression profile and LINC00271 is downregulated in malignancy', Surgery. https://doi.org/10.1016/j.surg.2019.04.067 Digital Object Identifier (DOI): 10.1016/j.surg.2019.04.067 Link: Link to publication record in Edinburgh Research Explorer Document Version: Peer reviewed version Published In: Surgery General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 07. Oct. 2021 Elsevier Editorial System(tm) for Surgery Manuscript Draft Manuscript Number: 19-AAES-22R2 Title: Adrenocortical tumors have a distinct long non-coding RNA expression profile and LINC00271 is downregulated in malignancy Article Type: AAES Society Paper Section/Category: Basic Research Keywords: LINC00271; adrenocortical; long noncoding RNA; microarray; prognostic marker; gene signaling pathway. Corresponding Author: Dr.
    [Show full text]
  • Genome Editing with CRISPR/Cas9 in Postnatal Mice Corrects PRKAG2 Cardiac Syndrome
    Cell Research (2016) 26:1099-1111. © 2016 IBCB, SIBS, CAS All rights reserved 1001-0602/16 $ 32.00 ORIGINAL ARTICLE www.nature.com/cr Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome Chang Xie1, 2, *, Ya-Ping Zhang3, *, Lu Song2, *, Jie Luo1, Wei Qi2, Jialu Hu3, Danbo Lu3, Zhen Yang3, Jian Zhang2, Jian Xiao1, Bin Zhou4, Jiu-Lin Du5, Naihe Jing2, Yong Liu1, Yan Wang1, Bo-Liang Li2, Bao-Liang Song1, Yan Yan3 1Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan 430072, China; 2The State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yue-Yang Road, Shanghai 200031, China; 3Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China; 4Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sci- ences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yue-Yang Road, Shanghai 200031, China; 5Institute of Neuroscience and State Key Laboratory of Neuroscience, Shanghai Institutes for Biological Sciences, Chinese Acade- my of Sciences, 320 Yue-Yang Road, Shanghai 200031, China PRKAG2 cardiac syndrome is an autosomal dominant inherited disease resulted from mutations in the PRK- AG2 gene that encodes γ2 regulatory subunit of AMP-activated protein kinase. Affected patients usually develop ventricular tachyarrhythmia and experience progressive heart failure that is refractory to medical treatment and requires cardiac transplantation. In this study, we identify a H530R mutation in PRKAG2 from patients with famil- ial Wolff-Parkinson-White syndrome. By generating H530R PRKAG2 transgenic and knock-in mice, we show that both models recapitulate human symptoms including cardiac hypertrophy and glycogen storage, confirming that the H530R mutation is causally related to PRKAG2 cardiac syndrome.
    [Show full text]
  • Transcriptomic Characterization of Fibrolamellar Hepatocellular
    Transcriptomic characterization of fibrolamellar PNAS PLUS hepatocellular carcinoma Elana P. Simona, Catherine A. Freijeb, Benjamin A. Farbera,c, Gadi Lalazara, David G. Darcya,c, Joshua N. Honeymana,c, Rachel Chiaroni-Clarkea, Brian D. Dilld, Henrik Molinad, Umesh K. Bhanote, Michael P. La Quagliac, Brad R. Rosenbergb,f, and Sanford M. Simona,1 aLaboratory of Cellular Biophysics, The Rockefeller University, New York, NY 10065; bPresidential Fellows Laboratory, The Rockefeller University, New York, NY 10065; cDivision of Pediatric Surgery, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065; dProteomics Resource Center, The Rockefeller University, New York, NY 10065; ePathology Core Facility, Memorial Sloan-Kettering Cancer Center, New York, NY 10065; and fJohn C. Whitehead Presidential Fellows Program, The Rockefeller University, New York, NY 10065 Edited by Susan S. Taylor, University of California, San Diego, La Jolla, CA, and approved September 22, 2015 (received for review December 29, 2014) Fibrolamellar hepatocellular carcinoma (FLHCC) tumors all carry a exon of DNAJB1 and all but the first exon of PRKACA. This deletion of ∼400 kb in chromosome 19, resulting in a fusion of the produced a chimeric RNA transcript and a translated chimeric genes for the heat shock protein, DNAJ (Hsp40) homolog, subfam- protein that retains the full catalytic activity of wild-type PKA. ily B, member 1, DNAJB1, and the catalytic subunit of protein ki- This chimeric protein was found in 15 of 15 FLHCC patients nase A, PRKACA. The resulting chimeric transcript produces a (21) in the absence of any other recurrent mutations in the DNA fusion protein that retains kinase activity.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • 32-3099: PRKAB1 Recombinant Protein Description
    9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982 Email: [email protected] 32-3099: PRKAB1 Recombinant Protein Alternative Name : AMPK,HAMPKb,5'-AMP-activated protein kinase subunit beta-1,AMPK subunit beta-1,AMPKb,PRKAB1. Description Source : E.coli. PRKAB1 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 293 amino acids (1-270 a.a.) and having a molecular mass of 32.8 kDa. The PRKAB1 is fused to a 23 amino acid His Tag at N- Terminus and purified by proprietary chromatographic techniques. 5'-AMP-activated protein kinase subunit beta-1 (PRKAB1) hinders protein, carbohydrate and lipid biosynthesis, in addition to cell growth and proliferation. AMPK is a heterotrimer comprised of an alpha catalytic subunit, and non-catalytic beta and gamma subunits. AMPK acts via direct phosphorylation of metabolic enzymes, and longer-term effects by phosphorylation of transcription regulators. PRKAB1 is a regulator of cellular polarity by remodeling the actin cytoskeleton; most likely by indirectly activating myosin. Beta non-catalytic subunit acts as a scaffold on which the AMPK complex compiles, through its C-terminus that joins alpha (PRKAA1 or PRKAA2) and gamma subunits (PRKAG1, PRKAG2 or PRKAG3). Product Info Amount : 5 µg Purification : Greater than 85% as determined by SDS-PAGE. The PRKAB1 protein solution (0.5mg/ml) contains 20mM Tris-HCl buffer (pH 8.0), 0.15M NaCl, Content : 10% glycerol and 1mM DTT. Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of Storage condition : time.
    [Show full text]
  • Age, DNA Methylation and the Malignant Potential of the Serrated Neoplasia Pathway Lochlan John Fennell B
    Age, DNA Methylation and the Malignant Potential of the Serrated Neoplasia Pathway Lochlan John Fennell B. Biomed Sci A thesis submitted for the degree of Doctor of Philosophy at The University of Queensland in 2020 Faculty of Medicine ORC ID: 0000-0003-3214-3527 1 Abstract Colorectal cancer is the third most common cancer in Australia and is responsible for the death of over four thousand Australians each year. There are two overarching molecular pathways leading to colorectal cancer. The conventional pathway, which is responsible for ~75% of colorectal cancer diagnoses, occurs in a step-wise manner and is the consequence of a series of genetic alterations including mutations of tumour suppressor genes and gross chromosomal abnormalities. This pathway has been extensively studied over the past three decades. The serrated neoplasia pathway is responsible for the remaining colorectal cancers. This pathway is triggered by oncogenic BRAF mutation and these cancers accumulate epigenetic alterations while progressing to invasive cancer. DNA methylation is important in serrated neoplasia, however the extent and role of DNA methylation on the initiation and progression of serrated lesions is not clear. DNA methylation accumulates in tissues with age, and advanced serrated lesions and cancers occur almost exclusively in elderly patients. How this methylation affects serrated lesions is unknown. In this thesis I set out to address three key research questions related to DNA methylation, age and serrated colorectal neoplasia. First, what is the extent of DNA methylation in colorectal cancers?; Second, Does age-related hypermethylation, and namely that occurring at the loci encoding tumour suppressor genes, increase the risk of serrated colorectal neoplasia?; and if true, how can we reconcile this with the existence of early onset serrated colorectal cancer? In the first chapter of this thesis, I examine the DNA methylation and transcriptional architecture of 216 colorectal cancer samples collected consecutively at the Royal Brisbane and Women’s hospital.
    [Show full text]
  • Human Kinome Profiling Identifies a Requirement for AMP-Activated
    Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection Laura J. Terrya, Livia Vastagb,1, Joshua D. Rabinowitzb, and Thomas Shenka,2 aDepartment of Molecular Biology and bDepartment of Chemistry and the Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ 08544 Contributed by Thomas Shenk, January 11, 2012 (sent for review December 29, 2011) Human cytomegalovirus (HCMV) modulates numerous cellular (7). Thus, the connections between AMPK activity and metabolic signaling pathways. Alterations in signaling are evident from the changes during HCMV infection have remained unclear. broad changes in cellular phosphorylation that occur during HCMV We confirmed the requirement for AMPK during infection, infection and from the altered activity of multiple kinases. Here we and we show that an AMPK antagonist, compound C, blocks report a comprehensive RNAi screen, which predicts that 106 cellular HCMV-induced changes to glycolysis and inhibits viral gene kinases influence growth of the virus, most of which were not expression. These studies argue that AMPK or a related, com- previously linked to HCMV replication. Multiple elements of the pound C-sensitive kinase is an essential contributor to metabolic AMP-activated protein kinase (AMPK) pathway scored in the screen. changes initiated by HCMV and provide unique insight into As a regulator of carbon and nucleotide metabolism, AMPK is poised potential antiviral strategies. to activate many of the metabolic pathways induced by HCMV infection. An AMPK inhibitor, compound C, blocked a substantial Results portion of HCMV-induced metabolic changes, inhibited the accumu- HumanKinomeScreenIdentifies Putative Effectors of HCMV Replication. lation of all HCMV proteins tested, and markedly reduced the We conducted an siRNA screen of the human kinome to perform an production of infectious progeny.
    [Show full text]
  • NFKBIZ Mutation Prevalence in the Arthur/Schmitz/Chapuy Cohorts
    Supplemental Tables/Figures: Table S1: NFKBIZ mutation prevalence in the Arthur/Schmitz/Chapuy cohorts. Subtype Cohort All ABC DLC Schmitz Chapuy # patients 1006 511 330 466 210 UTR 101 (10) 66 (13) 39 (12) 49 (11) 13 (6) Amplification 86 (8.5) 66 (12.9) 23 (7) 35 (8) 28 (13) NFKBIZ Mutation TOTAL 174 (17) 120 (23.5) 57 (17) 79 (17) 38 (18) Table S2: NFKBIZ 3′ UTR mutations in other WGS cohorts. Cohort # Patients NFKBIZ UTR mutations (%) Publication BL_Adult 81 1 (1.2) Grande_et_al,2019 BL_Pediatric 124 1 (0.8) unpublished DLBCL_cell_lines 15 2 (13.3) Morin_et_al,2013 DLBCL_BC 117 11 (9.4) Arthur_et_al,2018 DLBCL_ICGC 87 11 (12.6) Hübschmann_et_al,2021 FL_ICGC 100 4 (4) Hübschmann_et_al,2021 FL_Kridel 48 1 (2.1) Kridel_et_al,2016 Table S3: COO and LymphGen classifications of DLBCLs and FLs from other cohorts. NFKBIZ UTR mutations (%) DLBCL (%) FL (%) ABC 13 (41.9) 13 (54.2) 0 (0) GCB 4 (12.9) 4 (16.7) 0 (0) COO UNCLASS 2 (6.5) 2 (8.3) 0 (0) NA 12 (38.7) 5 (20.8) 5 (100) TOTAL 31 24 5 BN2 13 (41.9) 9 (37.5) 3 (60) EZB 4 (12.9) 2 (8.3) 2 (40) ST2 1 (3.2) 1 (4.2) 0 (0) LymphGen Other 9 (29) 8 (33.3) 0 (0) Composite 2 (6.5) 2 (8.3) 0 (0) NA 2 (6.5) 2 (8.3) 0 (0) TOTAL 31 24 5 Table S4: LymphGen classifications of all patients and those with NFKBIZ mutations in Arthur/Schmitz/Chapuy cohorts.
    [Show full text]
  • Supplementary Table 1. Pain and PTSS Associated Genes (N = 604
    Supplementary Table 1. Pain and PTSS associated genes (n = 604) compiled from three established pain gene databases (PainNetworks,[61] Algynomics,[52] and PainGenes[42]) and one PTSS gene database (PTSDgene[88]). These genes were used in in silico analyses aimed at identifying miRNA that are predicted to preferentially target this list genes vs. a random set of genes (of the same length). ABCC4 ACE2 ACHE ACPP ACSL1 ADAM11 ADAMTS5 ADCY5 ADCYAP1 ADCYAP1R1 ADM ADORA2A ADORA2B ADRA1A ADRA1B ADRA1D ADRA2A ADRA2C ADRB1 ADRB2 ADRB3 ADRBK1 ADRBK2 AGTR2 ALOX12 ANO1 ANO3 APOE APP AQP1 AQP4 ARL5B ARRB1 ARRB2 ASIC1 ASIC2 ATF1 ATF3 ATF6B ATP1A1 ATP1B3 ATP2B1 ATP6V1A ATP6V1B2 ATP6V1G2 AVPR1A AVPR2 BACE1 BAMBI BDKRB2 BDNF BHLHE22 BTG2 CA8 CACNA1A CACNA1B CACNA1C CACNA1E CACNA1G CACNA1H CACNA2D1 CACNA2D2 CACNA2D3 CACNB3 CACNG2 CALB1 CALCRL CALM2 CAMK2A CAMK2B CAMK4 CAT CCK CCKAR CCKBR CCL2 CCL3 CCL4 CCR1 CCR7 CD274 CD38 CD4 CD40 CDH11 CDK5 CDK5R1 CDKN1A CHRM1 CHRM2 CHRM3 CHRM5 CHRNA5 CHRNA7 CHRNB2 CHRNB4 CHUK CLCN6 CLOCK CNGA3 CNR1 COL11A2 COL9A1 COMT COQ10A CPN1 CPS1 CREB1 CRH CRHBP CRHR1 CRHR2 CRIP2 CRYAA CSF2 CSF2RB CSK CSMD1 CSNK1A1 CSNK1E CTSB CTSS CX3CL1 CXCL5 CXCR3 CXCR4 CYBB CYP19A1 CYP2D6 CYP3A4 DAB1 DAO DBH DBI DICER1 DISC1 DLG2 DLG4 DPCR1 DPP4 DRD1 DRD2 DRD3 DRD4 DRGX DTNBP1 DUSP6 ECE2 EDN1 EDNRA EDNRB EFNB1 EFNB2 EGF EGFR EGR1 EGR3 ENPP2 EPB41L2 EPHB1 EPHB2 EPHB3 EPHB4 EPHB6 EPHX2 ERBB2 ERBB4 EREG ESR1 ESR2 ETV1 EZR F2R F2RL1 F2RL2 FAAH FAM19A4 FGF2 FKBP5 FLOT1 FMR1 FOS FOSB FOSL2 FOXN1 FRMPD4 FSTL1 FYN GABARAPL1 GABBR1 GABBR2 GABRA2 GABRA4
    [Show full text]
  • Cardiogenetics Testing Reference Guide December 2018
    Cardiogenetics Testing reference guide December 2018 Why Choose Ambry More than 1 in 200 people have an inherited cardiovascular condition. Ambry’s mission is to provide the most advanced genetic testing information available to help you identity those at-risk and determine the best treatment options. If we know a patient has a disease-causing genetic change, not only does it mean better disease management, it also indicates that we can test others in the family and provide them with potentially life-saving information. Diseases and Testing Options cardiomyopathies arrhythmias Hypertrophic Cardiomyopathy (HCMNext) Catecholaminergic Polymorphic Ventricular Dilated Cardiomyopathy (DCMNext) Tachycardia (CPVTNext) Arrhythmogenic Right Ventricular Long QT Syndrome, Short QT Syndrome, Cardiomyopathy (ARVCNext) Brugada Syndrome (LongQTNext, RhythmNext) Cardiomyopathies (CMNext, CardioNext) Arrhythmias (RhythmNext, CardioNext) other cardio conditions Transthyretin Amyloidosis (TTR) familial hypercholesterolemia Noonan Syndrome (NoonanNext) and lipid disorders Hereditary Hemorrhagic Telangiectasia Familial Hypercholesterolemia (FHNext) (HHTNext) Sitosterolemia (Sitosterolemia Panel) Comprehensive Lipid Menu thoracic aortic aneurysms (CustomNext-Cardio) and dissections Familial Chylomicronemia Syndrome (FCSNext) Thoracic Aneurysms and Dissections, aortopathies (TAADNext) Marfan Syndrome (TAADNext) Ehlers-Danlos Syndrome (TAADNext) Targeted Panels Gene Comparison ALL PANELS HAVE A TURNAROUND TIME OF 2-3 WEEKS arrhythmias CPVTNext CPVTNext CASQ2,
    [Show full text]